ADCendo: Funding, Investors & Team (Sep 2026)
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
ADCendo has raised $261M across 4 funding rounds on record, the most recent a Series C of $75.0M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ADCendo Company Profile and Key Stats
Latest funding round on record: Apr 2026.
ADCendo Funding Rounds
ADCendo raised $34.0M in a Series A announced in Apr 2023.
1.1 years later, a Series A of $17.3M was announced in May 2024.
6 months later, a Series B of $135M was announced in Nov 2024.
1.4 years later, a Series C of $75.0M was announced in Apr 2026.
ADCendo Founders and Leadership Team
Contact details for the ADCendo team: 2 of 3 have an email address on file.
Start 14-day free trial →ADCendo Funding Compared to Other Biotechnology Startups
ADCendo's latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ADCendo in Biotechnology and Copenhagen
Companies Similar to ADCendo
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several…
Alcolase is a Danish life science start-up that specializes in alcohol flushing.
ENZIDIA is unleashing the biomanufacturing revolution with an enzyme acceleration revolution
Gefjon Pharma is a biopharmaceutical company focused on developing innovative solutions to combat…
Synuca Therapeutics focused on developing innovative therapies for neurological disorders, particularly…
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The…
Pioneering new sustainable bio-based ingredients
Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or…
EvodiaBio is a company in the bio-industrial sector that develops eco-friendly fragrances for the food and…
Fida Biosystems is a technology that provides the detection and characterization of proteins and…
Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived…
WiLD is a networking platform for women in senior positions in business and academia that is motivating and…
ADCendo Funding FAQs
What does ADCendo do?
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
How much funding has ADCendo raised?
ADCendo has raised $261M across 4 rounds on record. The most recent is a Series C of $75.0M announced in Apr 2026.
When did ADCendo last raise funding?
ADCendo's most recent funding round on record is a Series C of $75.0M, announced in Apr 2026.
Who founded ADCendo?
FundedIQ lists Henrik Stage (Founder), Lars H Engelholm (Founder), Michael Pehl (Founder) at ADCendo.
Where is ADCendo headquartered?
ADCendo is based in Copenhagen, Hovedstaden, Denmark.
How many employees does ADCendo have?
ADCendo is in the 11-50 employee band.
How does ADCendo's funding compare to other Biotechnology startups?
ADCendo's latest round of $75.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ADCendo Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ADCendo is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.